Subklewe Lab - Translational Cancer Immunology

The Laboratory for Translational Cancer Immunology develops immunotherapies for malignant neoplasia, with a special focus on acute leukemia and B-cell lymphoma. We seek to understand mechanisms of action and resistance of cellular- and antibody-based immunotherapy. The goal is to identify predictive biomarkers for selecting the suitable immunotherapy for each individual patient. Read more...

Selected Publications

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Philipp N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, Scheurer M, Muth A, Hänel G, Nixdorf D, Sponheimer M, Ohlmeyer M, Lacher SM, Brauchle B, Marcinek A, Rohrbacher L, Leutbecher A, Rejeski K, Weigert O, von Bergwelt-Baildon M, Theurich S, Kischel R, Jeremias I, Bücklein VL, Subklewe M.
Blood. 2022 Sep 8;140(10):1104-1118. doi: 10.1182/blood.2022015956. PubMed

Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML.
Nixdorf D, Sponheimer M, Berghammer D, Engert F, Bader U, Philipp N, Kazerani M, Straub T, Rohrbacher L, Wange L, Dapa S, Atar D, Seitz CM, Brandstetter K, Linder A, von Bergwelt M, Leonhardt H, Mittelstaet J, Kaiser A, Bücklein V, Subklewe M.
Leukemia. 2023 Jun;37(6):1298-1310. doi: 10.1038/s41375-023-01905-0. PubMed

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment.
Hänel G, Schönle A, Neumann AS, Nixdorf D, Philipp N, Sponheimer M, Leutbecher A, Emhardt AJ, Magno G, Bücklein V, Eckmann J, Dunshee D, Kramar V, Korfi K, Colombetti S, Umaña P, Klein C, Subklewe M.
Leukemia. 2024 Feb;38(2):398-402. doi: 10.1038/s41375-023-02127-0. PubMed

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.
Rejeski K, Perez A, Iacoboni G, Blumenberg V, Bücklein VL, Völkl S, Penack O, Albanyan O, Stock S, Müller F, Karschnia P, Petrera A, Reid K, Faramand R, Davila ML, Modi K, Dean EA, Bachmeier C, von Bergwelt-Baildon M, Locke FL, Bethge W, Bullinger L, Mackensen A, Barba P, Jain MD, Subklewe M.
Sci Adv. 2023 Sep 22;9(38):eadg3919. doi: 10.1126/sciadv.adg3919. PubMed

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody.
Augsberger C, Hänel G, Xu W, Pulko V, Hanisch L, Augustin A, Challier J, Hunt K, Vick B, Rovatti P, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz A, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin N, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umaña P, Klein C, Subklewe M.
Blood. 2021 Dec 23;138(25):2655-2669. doi: 10.1182/blood.2020010477. PubMed

CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger CS, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge WA, Ayuk F, Bachy E, Salles GA, Jain MD, Subklewe M.
Blood. 2021 Dec 16;138(24):2499-2513. doi: 10.1182/blood.2020010543. PubMed

Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.
Lichtenegger FS, Schnorfeil FM, Rothe M, Deiser K, Altmann T, Bücklein VL, Köhnke T, Augsberger C, Konstandin NP, Spiekermann K, Moosmann A, Boehm S, Boxberg M, Heemskerk MH, Goerlich D, Wittmann G, Wagner B, Hiddemann W, Schendel DJ, Kvalheim G, Bigalke I, Subklewe M.
Clin Transl Immunology. 2020 Mar 3;9(3):e1117. doi: 10.1002/cti2.1117. PubMed

More publications